These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38540686)

  • 41. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
    Zhu J; Wu Y; Yu Y; Li Y; Shen J; Zhang R
    Cell Death Dis; 2022 Aug; 13(8):727. PubMed ID: 35987690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
    Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H
    Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
    Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
    Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
    Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
    Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
    Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
    Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC
    Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
    Yuan W; Tao R; Huang D; Yan W; Shen G; Ning Q
    Aging (Albany NY); 2021 Jan; 13(3):3969-3993. PubMed ID: 33495404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
    Yang S; Wang XQ
    BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
    Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Xu W; Gong W; Shao L
    Gene; 2020 Aug; 753():144807. PubMed ID: 32461017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
    Nour MA; Kheradmand F; Rasmi Y; Baradaran B
    Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
    Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
    Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
    Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
    Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.